keyword
MENU ▼
Read by QxMD icon Read
search

CIBMTR

keyword
https://www.readbyqxmd.com/read/29079457/autologous-allogeneic-hematopoietic-cell-transplantation-hct-versus-tandem-autologous-transplantation-for-multiple-myeloma-comparison-of-long-term-post-relapse-survival
#1
Myo Htut, Anita D'Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, Edward Copelan, Siddhartha Ganguly, Mehdi Hamadani, Mohamed Kharfan-Dabaja, Hillard Lazarus, Cindy Lee, Kenneth Meehan, Taiga Nishihori, Ayman Saad, Sachiko Seo, Muthalagu Ramanathan, Saad Z Usmani, Christina Gasparetto, Tomer M Mark, Yago Nieto, Parameswaran Hari
We compared post-relapse overall survival (OS) after autologous-allogenenic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in multiple myeloma (MM). Post-relapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2000 and 2010 were analyzed. 404 patients (72.4%) relapsed in the auto/auto group and 178 patients (67.4%) relapsed in the auto/allo group after a median follow up of 8...
October 24, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032274/assessment-of-impact-of-hla-type-on-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-for-chronic-lymphocytic-leukemia
#2
Brian T Hill, Kwang Woo Ahn, Zhen-Huan Hu, Mahmoud Aljurf, Amer Beitinjaneh, Jean-Yves Cahn, Jan Cerny, Mohamed A Kharfan-Dabaja, Siddhartha Ganguly, Nilanjan Ghosh, Michael R Grunwald, Yoshihiro Inamoto, Tamila Kindwall-Keller, Taiga Nishihori, Richard F Olsson, Ayman Saad, Matthew Seftel, Sachiko Seo, Jeffrey Szer, Martin Tallman, Celalettin Ustun, Peter H Wiernik, Richard T Maziarz, Matt Kalaycio, Edwin Alyea, Uday Popat, Ronald Sobecks, Wael Saber
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the sole known curative treatment for CLL...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032272/fludarabine-and-busulfan-versus-fludarabine-cyclophosphamide-and-rituximab-as-reduced-intensity-conditioning-for-allogeneic-transplantation-in-follicular-lymphoma
#3
Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed, Vaishalee P Kenkre, Bipin Savani, Madan Jagasia, Nirav N Shah, Timothy S Fenske, Ana Sureda, Sonali M Smith, Mehdi Hamadani
Large, multicenter studies comparing commonly used reduced-intensity conditioning (RIC) approaches in follicular lymphoma (FL) have not been performed. Using the Center for International Blood and Marrow Transplant Research database, we report the outcomes of the 2 most commonly used RIC approaches, fludarabine and busulfan (Flu/Bu) versus fludarabine, cyclophosphamide, and rituximab (FCR) in FL patients. We evaluated 200 FL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received RIC with either Flu/Bu (n = 98) or FCR (n = 102) during 2008 to 2014...
October 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28945102/survival-after-stem-cell-transplant-in-pediatric-and-young-adult-patients-with-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia
#4
Alessandro Crotta, Jie Zhang, Christopher Keir
OBJECTIVE: Allogeneic stem-cell transplant (allo-SCT) is the standard of care for pediatric patients with acute lymphoblastic leukemia (ALL) who relapse after frontline chemotherapy; however, for patients who relapse after allo-SCT, outcomes are very poor. Few studies have examined overall survival in this patient population, particularly in patients who received a second allo-SCT. METHODS: This was a retrospective analysis using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry...
October 24, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28939455/neurocognitive-dysfunction-in-hematopoietic-cell-transplant-recipients-expert-review-from-the-late-effects-and-quality-of-life-working-committee-of-the-center-for-international-blood-and-marrow-transplant-research-and-complications-and-quality-of-life-working
#5
REVIEW
Debra Lynch Kelly, David Buchbinder, Rafael F Duarte, Jeffrey J Auletta, Neel Bhatt, Michael Byrne, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh Dalal, Andrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J Hayashi, Kehinde Adekola, Jason Law, Catherine J Lee, Jane Liesveld, Adriana K Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K Parsons, Angela Scherwath, Hannah-Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne Warwick, Baldeep M Wirk, Jean Yi, Minoo Battiwalla, Mary E Flowers, Bipin Savani, Bronwen E Shaw
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT...
September 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28869618/outcomes-following-autologous-hematopoietic-stem-cell-transplant-for-patients-with-relapsed-wilms-tumor-a-cibmtr-retrospective-analysis
#6
M H Malogolowkin, M T Hemmer, J Le-Rademacher, G A Hale, P A Mehta, A R Smith, C Kitko, A Abraham, H Abdel-Azim, C Dandoy, M Angel Diaz, R P Gale, G Guilcher, R Hayashi, S Jodele, K A Kasow, M L MacMillian, M Thakar, B M Wirk, A Woolfrey, E L Thiel
Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively...
November 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28865971/haploidentical-hematopoietic-stem-cell-transplantation-for-myelodysplastic-syndrome
#7
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
This study aimed to validate the capability of the Center for International Blood and Marrow Transplant Research (CIBMTR) prognostic scoring system to predict outcomes of patients with myelodysplastic syndromes (MDS) who had undergone HLA-haploidentical related donor hematopoietic stem cell transplantation (haplo-HSCT). We also propose and validate a more suitable prognostic scoring system. A total of 157 patients with MDS who underwent haplo-HSCT were enrolled. The CIBMTR prognostic scoring system could predict the 2-year clinical outcomes, but failed to predict the 100-day clinical outcomes after haplo-HSCT...
September 1, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28817182/centralized-patient-reported-outcome-data-collection-in-transplantation-is-feasible-and-clinically-meaningful
#8
Bronwen E Shaw, Ruta Brazauskas, Heather R Millard, Rachel Fonstad, Kathryn E Flynn, Amy Abernethy, Jenny Vogel, Charney Petroske, Deborah Mattila, Rebecca Drexler, Stephanie J Lee, Mary M Horowitz, J Douglas Rizzo
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) cures many patients, but often with the risk of late effects and impaired quality of life. The value of quantifying patient-reported outcomes (PROs) is increasingly being recognized, but the routine collection of PROs is uncommon. This study evaluated the feasibility of prospective PRO collection by an outcome registry at multiple time points from unselected HCT patients undergoing transplantation at centers contributing clinical data to the Center for International Blood and Marrow Transplant Research (CIBMTR), and then it correlated the PRO data with clinical and demographic data...
December 1, 2017: Cancer
https://www.readbyqxmd.com/read/28811306/replication-and-validation-of-genetic-polymorphisms-associated-with-survival-after-allogeneic-blood-or-marrow-transplant
#9
Ezgi Karaesmen, Abbas A Rizvi, Leah M Preus, Philip L McCarthy, Marcelo C Pasquini, Kenan Onel, Xiaochun Zhu, Stephen Spellman, Christopher A Haiman, Daniel O Stram, Loreall Pooler, Xin Sheng, Qianqian Zhu, Li Yan, Qian Liu, Qiang Hu, Amy Webb, Guy Brock, Alyssa I Clay-Gilmour, Sebastiano Battaglia, David Tritchler, Song Liu, Theresa Hahn, Lara E Sucheston-Campbell
Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms (SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality, progression-free survival, transplant-related mortality, and/or overall survival after BMT. Replication and validation of these SNP associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for International Blood and Marrow Transplant Research...
September 28, 2017: Blood
https://www.readbyqxmd.com/read/28674027/increasing-use-of-allogeneic-hematopoietic-cell-transplantation-in-patients-aged-70-years-and-older-in-the-united-states
#10
Lori Muffly, Marcelo C Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K Ballen, Ashish Bajel, Frederic Baron, Minoo Battiwalla, Amer Beitinjaneh, Jean-Yves Cahn, Mathew Carabasi, Yi-Bin Chen, Saurabh Chhabra, Stefan Ciurea, Edward Copelan, Anita D'Souza, John Edwards, James Foran, Cesar O Freytes, Henry C Fung, Robert Peter Gale, Sergio Giralt, Shahrukh K Hashmi, Gerhard C Hildebrandt, Vincent Ho, Ann Jakubowski, Hillard Lazarus, Marlise R Luskin, Rodrigo Martino, Richard Maziarz, Philip McCarthy, Taiga Nishihori, Rebecca Olin, Richard F Olsson, Attaphol Pawarode, Edward Peres, Andrew R Rezvani, David Rizzieri, Bipin N Savani, Harry C Schouten, Mitchell Sabloff, Matthew Seftel, Sachiko Seo, Mohamed L Sorror, Jeff Szer, Baldeep M Wirk, William A Wood, Andrew Artz
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ≥70 years with hematologic malignancies across the United States. Adults ≥70 years with a hematologic malignancy undergoing first allogeneic HCT in the United States between 2000 and 2013 and reported to the Center for International Blood and Marrow Transplant Research were eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and transplant-related mortality (TRM) were studied...
August 31, 2017: Blood
https://www.readbyqxmd.com/read/28606646/current-use-and-trends-in-hematopoietic-cell-transplantation-in-the-united-states
#11
EDITORIAL
Anita D'Souza, Stephanie Lee, Xiaochun Zhu, Marcelo Pasquini
Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve...
September 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28606176/rituximab-containing-reduced-intensity-conditioning-improves-progression-free-survival-following-allogeneic-transplantation-in-b-cell-non-hodgkin-lymphoma
#12
Narendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, Madan Jagasia, Alyssa DiGilio, Steven M Devine, Samantha Jaglowski, Vanessa Kennedy, Andrew R Rezvani, Sonali M Smith, Anna Sureda, Timothy S Fenske, Mohamed A Kharfan-Dabaja, Phillipe Armand, Mehdi Hamadani
BACKGROUND: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-NHL. METHODS: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens...
June 12, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28529613/long-term-outcome-of-inflammatory-breast-cancer-compared-to-non-inflammatory-breast-cancer-in-the-setting-of-high-dose-chemotherapy-with-autologous-hematopoietic-cell-transplantation
#13
Yee Chung Cheng, Yushu Shi, Mei-Jie Zhang, Ruta Brazauskas, Michael T Hemmer, Michael R Bishop, Yago Nieto, Edward Stadtmauer, Lois Ayash, Robert Peter Gale, Hillard Lazarus, Leona Holmberg, Michael Lill, Richard F Olsson, Baldeep Mona Wirk, Mukta Arora, Parameswaran Hari, Naoto Ueno
Introduction: Inflammatory breast cancer (IBC) is a rare aggressive form of breast cancer. It is well known that the long-term survival and progression-free survival of IBC are worse than that of non-IBC. We report the long term outcomes of patients with IBC and non-IBC who had undergone high-dose chemotherapy (HDC) with autologous hematopoietic cell transplantation (AHCT). Methods: All 3387 patients with IBC or non-IBC who underwent HDC with AHCT between1990-2002 and registered with CIBMTR were included in this analysis...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28472539/hispanics-have-the-lowest-stem-cell-transplant-utilization-rate-for-autologous-hematopoietic-cell-transplantation-for-multiple-myeloma-in-the-united-states-a-cibmtr-report
#14
Jeffrey R Schriber, Parameswaran N Hari, Kwang Woo Ahn, Mingwei Fei, Luciano J Costa, Mohamad A Kharfan-Dabaja, Miguel Angel-Diaz, Robert P Gale, Siddharatha Ganguly, Saulius K Girnius, Shahrukh Hashmi, Attaphol Pawarode, David H Vesole, Peter H Wiernik, Baldeep M Wirk, David I Marks, Taiga Nishihori, Richard F Olsson, Saad Z Usmani, Tomer M Mark, Yago L Nieto, Anita D'Souza
BACKGROUND: Race/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States. METHODS: The Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived...
August 15, 2017: Cancer
https://www.readbyqxmd.com/read/28450183/hematopoietic-stem-cell-transplantation-activity-in-pediatric-cancer-between-2008-and-2014-in-the-united-states-a-center-for-international-blood-and-marrow-transplant-research-report
#15
Pooja Khandelwal, Heather R Millard, Elizabeth Thiel, Hisham Abdel-Azim, Allistair A Abraham, Jeffery J Auletta, Farid Boulad, Valerie I Brown, Bruce M Camitta, Ka Wah Chan, Sonali Chaudhury, Morton J Cowan, Miguel Angel-Diaz, Shahinaz M Gadalla, Robert Peter Gale, Gregory Hale, Kimberly A Kasow, Amy K Keating, Carrie L Kitko, Margaret L MacMillan, Richard F Olsson, Kristin M Page, Adriana Seber, Angela R Smith, Anne B Warwick, Baldeep Wirk, Parinda A Mehta
This Center for International Blood and Marrow Transplant Research report describes the use of hematopoietic stem cell transplantation (HSCT) in pediatric patients with cancer, 4408 undergoing allogeneic (allo) and3076 undergoing autologous (auto) HSCT in the United States between 2008 and 2014. In both settings, there was a greater proportion of boys (n = 4327; 57%), children < 10 years of age (n = 4412; 59%), whites (n = 5787; 77%), and children with a performance score ≥ 90% at HSCT (n = 6187; 83%)...
August 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28411175/risk-factors-for-subsequent-central-nervous-system-tumors-in-pediatric-allogeneic-hematopoietic-cell-transplant-a-study-from-the-center-for-international-blood-and-marrow-transplant-research-cibmtr
#16
Melissa Gabriel, Bronwen E Shaw, Ruta Brazauskas, Min Chen, David A Margolis, Henrik Sengelov, Ann Dahlberg, Ibrahim A Ahmed, David Delgado, Hillard M Lazarus, Brenda Gibson, Kasiani C Myers, Rammurti T Kamble, Aly Abdel-Mageed, Chi-Kong Li, Mary E D Flowers, Minoo Battiwalla, Bipin N Savani, Navneet Majhail, Peter J Shaw
Survivors of hematopoietic cell transplantation (HCT) are at risk of subsequent solid tumors, including central nervous system (CNS) tumors. The risk of CNS tumors after HCT in pediatric HCT recipients is not known. We evaluated the incidence and risk factors for CNS tumors in pediatric recipients of allogeneic HCT reported to the Center for International Blood and Marrow Transplant Research between 1976 and 2008. A case control design was used. There were no CNS tumors in the nonmalignant cohort (n = 4543) or in those undergoing HCT for solid tumors (n = 26)...
August 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28389255/relative-telomere-length-before-hematopoietic-cell-transplantation-and-outcome-after-unrelated-donor-hematopoietic-cell-transplantation-for-acute-leukemia
#17
Youjin Wang, Tao Wang, Casey Dagnall, Michael Haagenson, Stephen R Spellman, Belynda Hicks, Kristine Jones, Stephanie J Lee, Sharon A Savage, Shahinaz M Gadalla
Telomeres are tandem nucleotide repeats and a protein complex located at the end of the chromosomes maintaining genomic stability. Their potential as a predictive biomarker for outcomes after allogeneic hematopoietic cell transplant (HCT) in hematologic malignancies is still unclear. From the Center for International Blood and Marrow Transplant Research we randomly selected 536 acute leukemia patients from those who underwent myeloablative 8/8 HLA-matched unrelated donor HCT between 2005 and 2012 and who had an available pre-HCT blood sample in the repository...
July 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28346419/evolving-concepts-in-prognostic-scoring-of-chronic-gvhd
#18
REVIEW
A Lazaryan, M Arora
Chronic GvHD (cGvHD) remains one of the most complex and challenging complications after allogeneic hematopoietic cell transplantation. Emerging knowledge about the clinical manifestations and associated organ involvement of cGvHD has led to the establishment of prognostic parameters for post-transplant survival among affected allograft recipients. Studies employing the pre-National Institutes of Health (NIH) consensus data on cGvHD incidence and its risks have led to development of the CIBMTR's cGvHD risk stratification, which serves as the most refined and validated prognostic tool for estimating survival of patients with cGvHD...
October 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28214979/improved-prognostic-stratification-power-of-cibmtr-risk-score-with-the-addition-of-absolute-lymphocyte-and-eosinophil-counts-at-the-onset-of-chronic-gvhd
#19
Joon Ho Moon, Nada Hamad, Sang Kyun Sohn, Jieun Uhm, Naheed Alam, Vikas Gupta, Jeffrey H Lipton, Hans A Messner, Matthew Seftel, John Kuruvilla, Dennis Dong Hwan Kim
The CIBMTR chronic graft-versus-host disease (cGVHD) risk score can be refined and improved for better prognostic stratification. Three hundred and seven consecutive patients diagnosed with cGVHD by the NIH consensus criteria were retrospectively reviewed and had the CIBMTR risk score applied and analyzed. The CIBMTR risk score was successfully validated in our cohort (n = 307). The 3-year overall survival (OS) rates in each risk group (RG) were 82.5 ± 11.3% (RG1), 79.4 ± 3.0% (RG2), 71.8 ± 6.3% (RG3), and 27...
May 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28161608/allogeneic-hematopoietic-cell-transplantation-for-aggressive-nk-cell-leukemia-a-center-for-international-blood-and-marrow-transplant-research-analysis
#20
Mehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M Smith, Jong Wook Lee, Ernesto Ayala, Nelson Chao, Parameswaran Hari, Javier Bolaños-Meade, Ronald Gress, Niels Smedegaard Anderson, Yi-Bin Chen, Umar Farooq, Gary Schiller, Jean Yared, Anna Sureda, Timothy S Fenske, Horatiu Olteanu
Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease...
May 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
115199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"